Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 31, 2024
Daily News
July 31, 2024
- Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
July 31, 2024
- Novo’s Cell Therapy Partner Heartseed Goes Public on TSE
July 31, 2024
- Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
- Foreign Pharma Sales in Japan Likely to Fall for 2nd Straight Year in 2024: Fuji Keizai
July 31, 2024
- Japan OKs FY2025 Budget Ceiling, 410 Billion Yen for Social Security Cost Rise
July 31, 2024
- JCR Ditches Temcell Program for nHIE Indication
July 31, 2024
- MHLW Council Begins Discussions on Rx-to-OTC Switch of 3 New APIs
July 31, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…